PAK4 and neoplasm: Our previous report demonstrated that treatment with PF-3758309, a PAK4 inhibitor, produced maximal tumour growth inhibition when combined with gemcitabine in TKCC15-cell-derived tumours, which are comparatively more sensitive to gemcitabine (IC50 ≈ 5 nM) than PANC-1 cell lines [82].